:BeiGene (688276.SH): The clinical trial application for the influenza viral lysate vaccine (BK-01 adjuvant) has been approved.

Wisdom Finance News App, Baike Biotech (688276.SH) announced that the company has recently received the "Drug Clinical Trial Approval Notification" for the influenza virus split vaccine (BK-01 adjuvant) issued by the National Medical Products Administration. This time, the company has been approved for clinical trials of the influenza virus split vaccine (BK-01 adjuvant) for people aged 60 and above. After vaccination, it can stimulate the body to produce a stronger immune response and be used to prevent influenza caused by the influenza virus. This vaccine adopts the technology route of influenza virus split vaccine, combined with the adjuvant independently developed by the company, to ensure the safety of the vaccine while enhancing the antigenicity of the vaccine. Compared with traditional split influenza vaccines, it can stimulate the body to produce higher levels of protective antibodies.